format
A data frame containing:
ll{
time time to event
status censoring status: 0=censoring, 1=HAART initiation, 2=AIDS/Death before HAART
ageatfda age in years at time of FDA approval of first protease inhibitor
idu history of IDU: 0=no history, 1=history
black race: 0=not African-American; 1=African-American
cd4nadir CD4 count (per 100 cells/ul)
}source
Study included 1164 women enrolled in WIHS, who were alive, infected
with HIV, and free of clinical AIDS on December, 1995, when the first
protease inhibitor (saquinavir mesylate) was approved by the Federal
Drug Administration. Women were followed until the first of the
following occurred: treatment initiation, AIDS diagnosis, death, or
administrative censoring (September, 2006). Variables included history
of injection drug use at WIHS enrollment, whether an individual was
African American, age, and CD4 nadir prior to baseline.